Montelukast Amarox

Montelukast, the active ingredient in Montelukast Amarox, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is prescribed to manage asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in adults and children.

GNH USA supplies Montelukast Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets.

Montelukast is a leukotriene receptor antagonist used to treat conditions mediated by leukotriene‑driven inflammation.

Asthma: improves control and reduces frequency of bronchospasm. Allergic rhinitis: relieves nasal congestion, sneezing and itching. Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Cough: transient irritation. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema, or anaphylaxis. - Mood changes: depression, anxiety, or suicidal thoughts. - Liver enzyme elevation: abnormal hepatic function tests.

Montelukast should be used with awareness of specific safety considerations. - Pregnancy: consult a healthcare provider as safety data are limited. - Breastfeeding: use only if the benefit outweighs potential risk. - Drug interactions: review all concomitant medications for possible effects. - Renal/hepatic impairment: dose may need adjustment based on clinical judgment. - Age considerations: safety in children under 12 requires prescriber guidance. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Montelukast may interact with several medicines; monitoring is advised.

Major Interactions (Avoid): - Phenobarbital: may reduce montelukast plasma concentrations. - Rifampin: may decrease therapeutic effectiveness. - Ketoconazole: may increase montelukast levels.

Moderate Interactions (Monitor Closely): - Warfarin: potential enhancement of anticoagulant effect. - Beta‑agonists: additive bronchodilation may occur. - ACE inhibitors: possible increase in cough frequency.